INVEGA TRINZA® Metabolic Data Observed

Metabolic Change Data: Long-term Maintenance Trial1

metabolic-data-weight-change

*During the open-label phase, patients received several doses of INVEGA SUSTENNA® (paliperidone palmitate) followed by a single dose of INVEGA TRINZA®.

WEIGHT GAIN: Weight gain has been reported with atypical antipsychotic use. Clinical monitoring of weight is recommended.1

Fasting Glucose1

metabolic-data-long-term

*During the open-label phase, patients received several doses of INVEGA SUSTENNA® followed by a single dose of INVEGA TRINZA®.

Hyperglycemia and Diabetes Mellitus1

  • Monitor for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia, and weakness
  • Monitor glucose regularly in patients with diabetes or at risk for diabetes

Fasting Lipids1

fasting-lipids

DYSLIPIDEMIA: Undesirable alterations in lipids have been observed in patients treated with antipsychotics.1

Please see additional Important Safety Information below.

*Values for the open-label phase and the double-blind phase are relative to their respective baselines.

†During the open-label phase, patients received several doses of INVEGA SUSTENNA® followed by a single dose of INVEGA TRINZA®.

Reference: 1. INVEGA TRINZA® [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc.; January 2019.